2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N10871
    Neocryptomerin
    		Inhibitor 99.14%
    Neocryptomerin, a biflavonoid, shows inhibitory activity against U251, MCF-7, HeLa cell. Neocryptomerin has favorable binding affinities in the active pocket of SARS-CoV-2. Neocryptomerin is the leading compound of rational compounds against COVID-19.
    Neocryptomerin
  • HY-N2949
    Bonducellpin D
    		Inhibitor ≥98.0%
    Bonducellpin D is a furanoditerpenoid lactone isolated from Caesalpinia minax. Bonducellpin D exhibits broad-spectrum inhibition potential against SARS-CoV Mpro and MERS-CoV Mpro, with an Ki of 467.11 and 284.86 nM, respectively. Bonducellpin D also exhibits moderate anti-cancer activity in vitro.
    Bonducellpin D
  • HY-149264
    SARS-CoV-2 3CLpro-IN-13
    		Inhibitor ≥99.0%
    SARS-CoV-2 3CLpro-IN-13 is a potent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 21 nM. SARS-CoV-2 3CLpro-IN-13 shows anti-coronavirus activity.
    SARS-CoV-2 3CLpro-IN-13
  • HY-100304
    KW-8232 free base
    		Inhibitor
    KW-8232 free base, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
    KW-8232 free base
  • HY-138102
    SSAA09E3
    		Inhibitor 98.01%
    SSAA09E3 is a SARS-CoV entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC50 of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC50 of 0.15 μM.
    SSAA09E3
  • HY-P4388
    Z-Arg-Leu-Arg-Gly-Gly-AMC
    		99.93%
    Z-Arg-Leu-Arg-Gly-Gly-AMC is a peptide substrate of SARS-CoV PLpro.
    Z-Arg-Leu-Arg-Gly-Gly-AMC
  • HY-B0372AS
    Bromhexine-d3 hydrochloride
    		Inhibitor ≥99.0%
    Bromhexine-d3 (hydrochloride) is deuterium labeled Bromhexine (hydrochloride). Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions[1][2][3][4].
    Bromhexine-d<sub>3</sub> hydrochloride
  • HY-139908
    MERS-CoV-IN-1
    		Inhibitor 99.53%
    MERS-CoV-IN-1 exhibits excellent inhibitory activity against coronavirus. MERS-CoV-IN-1 is useful as a pharmaceutical composition for preventing coronavirus-induced diseases (MERS-CoV and SARS) (extracted from patent WO2018174442A1, compound 1).
    MERS-CoV-IN-1
  • HY-156346
    HCoV-OC43-IN-1
    		Inhibitor 99.25%
    HCoV-OC43-IN-1 (Compound IV-16) is a coronavirus HCoV-OC43 inhibitor. HCoV-OC43-IN-1 has antiviral efficacy (EC50: 90 nM). HCoV-OC43-IN-1 inhibits the mRNA level and expression of viral nucleocapsid protein (NP).
    HCoV-OC43-IN-1
  • HY-137984
    Cnicin
    		Inhibitor 99.88%
    Cnicin is an orally bioavailable sesquiterpene lactone. Cnicin has antibacterial and antiproliferative properties and induces apoptosis in primary myeloma cells. Cnicin also exhibits activity against SARS-CoV-2. Cnicin inhibits the viral replication of SARS CoV-2 with an IC50 of 1.18 μg/mL. Cnicin can promote functional nerve regeneration.
    Cnicin
  • HY-14648S5
    Dexamethasone-d3-1
    		Inhibitor 98.02%
    Dexamethasone-d3-1 (Hexadecadrol-d3-1; Prednisolone F-d3-1) is a deuterium labeled Dexamethasone (HY-14648). Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d<sub>3</sub>-1
  • HY-139165B
    AT-9010 triethylamine
    		Inhibitor
    AT-9010 triethylamine，a triphosphate active metabolite of AT-527，is a potent inhibitor of NiRAN (a function essential for viral replication). AT-9010 triethylamine can inhibit SARS-CoV-2 replication.
    AT-9010 triethylamine
  • HY-N8306
    Isojacareubin
    		Inhibitor ≥98.0%
    Isojacareubin can be isolated from Hypericum japonicum. Isojacareubin covalently inhibits SARS-CoV-2 3CLpro. Isojacareubin also has anti-helicobacter activity. Isojacareubin inhibits PKC, and suppresses hepatocellular carcinoma metastasis and induces apoptosis.
    Isojacareubin
  • HY-172437
    Secutrelvir
    		Inhibitor 99.64%
    Secutrelvir is the inhibitor for 3CL protease that exhibits antiviral activity through inhibition of SARS-CoV-2 replication.
    Secutrelvir
  • HY-N8471
    Niazinin
    		Inhibitor 99.94%
    Niazinin is a thiocarbamate glycoside with antileishmanial activities, with an IC50 value of 5.25 μM. Niazinin also shows a binding affinity with the target protein 3CL protease. Niazinin has promising leishmanicidal, anti-inflammatory and anti-pyretic activity.
    Niazinin
  • HY-136597
    Remdesivir O-desphosphate acetonide impurity
    		Inhibitor 99.88%
    Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.
    Remdesivir O-desphosphate acetonide impurity
  • HY-146998
    SARS-CoV-2 3CLpro-IN-2
    		Inhibitor 99.71%
    SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases.
    SARS-CoV-2 3CLpro-IN-2
  • HY-N9351
    Cleistanthin B
    		Inhibitor ≥99.0%
    Cleistanthin B (Diphyllin O-glucoside) is an orally active arylnaphthalene lignan lactone glycoside. Cleistanthin B exhibits anti-SARS-CoV-2 effects in Vero cells, with EC50 of 6.51 µM. Cleistanthin B also exhibits antitumor, diuretic and antihypertensive effects in vivo.
    Cleistanthin B
  • HY-P99947
    Rimteravimab
    		Inhibitor ≥99%
    Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2.
    Rimteravimab
  • HY-121620S
    Monolaurin-d23
    Monolaurin-d23 is the deuterium labeled Monolaurin[1]. Monolaurin (1-Monolaurin) possesses anti-viral and anti-bacterial activity[2][3].
    Monolaurin-d<sub>23</sub>
Cat. No. Product Name / Synonyms Species Source